V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003534 | 210013305 | 1.57 | 76.3 | Adjuvant (A) | null | 2020-06-18 | Docetaxel | null | N | DOCETAXEL | 100107612 |
| 210003536 | 210013306 | null | 62 | null | null | 2019-08-31 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 101491473 |
| 210003539 | 210013307 | null | 69.4 | Palliative (P) | 2021-08-20 | 2021-08-28 | Docetaxel 100mg/m2 (21 day) | null | N | DOCETAXEL | 101108235 |
| 210003542 | 210013309 | 1.68 | 55.2 | Adjuvant (A) | 2020-05-06 | 2020-05-07 | EC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101043355 |
| 210003551 | 210013312 | 1.5 | 58.2 | null | 2020-10-30 | 2020-10-30 | Docetaxel 75mg/m2 (21 day) | null | null | DOCETAXEL | 100945543 |
| 210003588 | 210013315 | 1.77 | 93.8 | null | 2019-08-02 | 2019-08-30 | Docetaxel | 02 | null | DOCETAXEL | 100005171 |
| 210003592 | 210013316 | 1.57 | 63.9 | Adjuvant (A) | null | 2020-10-15 | Trastuzumab | 02 | N | TRASTUZUMAB | 100779494 |
| 210003596 | 210013318 | null | null | Adjuvant (A) | 2017-12-03 | 2017-12-19 | Paclitaxel 7 day | 02 | null | PACLITAXEL | 100932729 |
| 210003608 | 210013319 | null | 63.5 | null | null | 2019-02-24 | Docetaxel | null | null | DOCETAXEL | 101459971 |
| 210003610 | 210013320 | 1.75 | 87.6 | Adjuvant (A) | 2020-02-12 | 2020-02-19 | Docetaxel | null | N | DOCETAXEL | 101694091 |
| 210003614 | 210013321 | 1.51 | 83.4 | null | 2021-02-28 | 2021-03-09 | TRASTUZUMAB | 02 | null | TRASTUZUMAB | 100051436 |
| 210003622 | 210013323 | 1.58 | null | Neo-adjuvant (N) | null | 2019-01-30 | Docetaxel 100mg/m2 (21 day) | 2 | N | DOCETAXEL | 100628901 |
| 210003628 | 210013324 | null | 59 | Curative (C) | 2020-07-19 | 2020-07-29 | Docetaxel | N | null | DOCETAXEL | 100983156 |
| 210003629 | 210013325 | 1.73 | 55.4 | Neo-adjuvant (N) | null | 2018-12-09 | Docetaxel 100mg/m2 (21 day) | 02 | N | DOCETAXEL | 101399238 |
| 210003633 | 210013326 | null | 91 | null | 2016-01-18 | 2017-11-20 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100306543 |
| 210003634 | 210013327 | 1.73 | 63.3 | null | 2018-07-17 | 2018-07-20 | EC | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101537298 |
| 210003638 | 210013330 | 1.68 | 61 | Adjuvant (A) | null | 2018-01-09 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100694326 |
| 210003641 | 210013331 | 1.75 | 77.1 | Adjuvant (A) | 2019-11-19 | 2020-02-16 | PACLITAXEL | 02 | N | PACLITAXEL | 100075897 |
| 210003648 | 210013335 | 1.64 | 86.8 | Adjuvant (A) | null | 2021-10-31 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100213352 |
| 210003662 | 210013337 | 1.65 | 50.5 | Palliative (P) | null | 2018-08-29 | Paclitaxel 7 day | N | N | PACLITAXEL | 100138986 |
| 210003667 | 210013338 | 1.96 | 70.25 | null | null | 2021-05-07 | Docetaxel 100mg/m2 (21 day) | 02 | null | DOCETAXEL | 100691223 |
| 210003673 | 210013341 | 1.57 | 64.3 | Adjuvant (A) | null | 2021-10-05 | EC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100881847 |
| 210003675 | 210013342 | null | 68.9 | null | null | 2017-05-20 | Trastuzumab | null | N | TRASTUZUMAB | 100967742 |
| 210003677 | 210013343 | 1.55 | 0 | Adjuvant (A) | 2019-08-11 | 2019-11-02 | CYCLOPHOSPHAMIDE + EPIRUBICIN | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101174176 |
| 210003679 | 210013344 | 1.55 | 98.8 | Palliative (P) | 2019-11-17 | 2020-02-08 | TRASTUZUMAB | 02 | N | TRASTUZUMAB | 101863233 |
| 210003686 | 210013345 | 1.58 | 112.4 | Neo-adjuvant (N) | null | 2021-02-27 | Trastuzumab | 02 | N | TRASTUZUMAB | 101457830 |
| 210003689 | 210013346 | 1.74 | 61.2 | Palliative (P) | null | 2021-03-29 | Capecitabine | 02 | N | CAPECITABINE | 101857012 |
| 210003690 | 210013347 | 1.63 | 96.7 | Adjuvant (A) | 2021-12-21 | 2022-03-22 | Cyclophosphamide + Docetaxel | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100856400 |
| 210003691 | 210013348 | 1.6 | 70.2 | null | 2019-01-20 | 2019-05-03 | Carboplatin 21day + Paclitaxel 7day | 02 | null | TRASTUZUMAB EMTANSINE | 100478792 |
| 210003697 | 210013350 | 1.47 | 85.3 | Neo-adjuvant (N) | 2018-06-06 | 2018-07-06 | Paclitaxel albumin (Abraxane) 7 day | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100712049 |
| 210003698 | 210013351 | null | 63.3 | null | 2021-03-20 | 2021-04-03 | Eribulin | null | null | ERIBULIN | 100105527 |
| 210003703 | 210013352 | 1.49 | 0 | Palliative (P) | 2021-01-05 | 2021-01-12 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 101702403 |
| 210003712 | 210013353 | null | null | null | null | 2020-08-18 | Eribulin | 02 | null | NAB-PACLITAXEL | 101840371 |
| 210003716 | 210013355 | 1.74 | 63.8 | Adjuvant (A) | null | 2021-01-31 | null | 01 | N | LETROZOLE + PALBOCICLIB | 100856886 |
| 210003719 | 210013357 | null | null | null | 2019-07-02 | 2019-09-22 | Pertuzumab + Trastuzumab IV | null | null | PERTUZUMAB + TRASTUZUMAB | 101426308 |
| 210003720 | 210013358 | 1.75 | 77.4 | Neo-adjuvant (N) | 2021-04-25 | 2021-11-26 | GemCarbo Days 1+8 | null | null | CARBOPLATIN + GEMCITABINE | 101512375 |
| 210003721 | 210013359 | null | 120.6 | null | 2020-05-01 | 2020-06-24 | Capecitabine | null | null | CAPECITABINE | 100577965 |
| 210003723 | 210013361 | 1.72 | 84.5 | Palliative (P) | null | 2020-02-22 | Trial Unspecified | 02 | N | CARBOPLATIN + DOCETAXEL | 100832036 |
| 210003725 | 210013362 | 1.68 | 59.6 | Adjuvant (A) | 2017-12-06 | 2018-01-04 | Capecitabine | 02 | N | CAPECITABINE | 100388097 |
| 210003727 | 210013363 | 1.6 | 63 | Neo-adjuvant (N) | 2018-11-08 | 2018-11-14 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 101141121 |
| 210003728 | 210013364 | null | null | Neo-adjuvant (N) | 2018-12-19 | 2018-12-20 | Trial Unspecified | 01 | N | GEMCITABINE | 100605706 |
| 210003729 | 210013365 | 1.53 | 93.65 | Curative (C) | null | 2020-05-05 | Capecitabine | 02 | N | CAPECITABINE | 100347717 |
| 210003735 | 210013366 | 1.72 | 127.9 | null | 2019-09-06 | 2019-09-06 | Neratinib | 02 | null | NERATINIB | 100843950 |
| 210003736 | 210013367 | 1.68 | 100.3 | Adjuvant (A) | null | 2019-11-19 | Cyclophosphamide + Docetaxel | 02 | N | PALBOCICLIB | 101855705 |
| 210003742 | 210013369 | 1.55 | 69.7 | Adjuvant (A) | 2021-03-08 | 2021-04-09 | Trastuzumab(Kadcyla®) (Maintenance) | 02 | null | FEC | 100243128 |
| 210003743 | 210013370 | 1.5 | 106.5 | Neo-adjuvant (N) | 2021-04-07 | 2021-04-19 | Eribulin | 02 | N | ERIBULIN | 100196066 |
| 210003748 | 210013371 | 1.74 | 68 | Palliative (P) | 2017-05-24 | 2017-05-31 | null | 02 | N | FLUOROURACIL + OXALIPLATIN | 101091256 |
| 210003749 | 210013372 | 1.58 | 71.4 | null | 2020-12-20 | 2020-12-30 | Pertuzumab (Maintenance) | 02 | null | PERTUZUMAB | 101397605 |
| 210003750 | 210013373 | 1.58 | 0 | Neo-adjuvant (N) | 2021-12-13 | 2022-04-03 | Capecitabine | 02 | N | CAPECITABINE | 101617762 |
| 210003751 | 210013374 | 1.6 | 59.6 | null | null | 2021-05-20 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 101566613 |